NuVasive(NASDAQ:NUVA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 26, 2016. Company reported revenue of $236.21M. Analysts estimated a revenue of $232.86M. Earnings per share were $0.40. Analysts had estimated an EPS of $0.36.
In a different note, On Jul 13, 2016, JP Morgan said it Upgrades its rating on NuVasive. In the research note, the firm Raises the price-target to $55.00 per share. The shares have been rated ‘Overweight’ by the firm. On May 27, 2016, Barclays said it Upgrades its rating on NuVasive. In the research note, the firm Raises the price-target to $58.00 per share. The shares have been rated ‘Overweight’ by the firm.
NuVasive (NUVA) made into the market gainers list on Fridays trading session with the shares advancing 0.29% or 0.18 points. Due to strong positive momentum, the stock ended at $62.2, which is also near the day’s high of $62.42. The stock began the session at $61.9 and the volume stood at 5,32,231 shares. The 52-week high of the shares is $62.95 and the 52 week low is $36.81. The company has a current market capitalization of $3,123 M and it has 5,02,14,449 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, Jason Hannon (EVP, International) sold 14,534 shares at $57.92 per share price.Also, On Jan 7, 2016, Patrick Miles (President and COO) sold 10,723 shares at $54.41 per share price.On Dec 7, 2015, Quentin S. Blackford (CFO and CAO) sold 15,000 shares at $51.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.